[Tumor markers in lung cancer]

Area of Science:

• Oncology
• Biomarkers
• Cancer Diagnostics

Context:

• Lung cancer diagnosis and monitoring rely on various tumor markers.
• Specific markers show sensitivity for different lung cancer subtypes: CEA for adenocarcinoma, SCC and CYFRA for squamous cell carcinoma, and NSE and proGRP for small cell carcinoma.
• Tumor markers are crucial for tracking disease progression and treatment response.

Purpose:

• To evaluate the utility of different lung cancer tumor markers, including Carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC), neuron-specific enolase (NSE), cytokeratin 19 fragment (CYFRA), and pro-gastrin-releasing peptide (proGRP).
• To determine the most effective markers for monitoring specific lung cancer subtypes and predicting disease outcomes.
• To explore the role of CEA in predicting mediastinal lymph node metastasis in non-small cell lung cancer.

Summary:

• Serum pro-gastrin-releasing peptide (proGRP) levels more accurately reflect the disease course in small cell lung cancer patients compared to NSE or CEA.
• High serum CEA levels, adenocarcinoma histology, and large tumor size are significant predictors of pathologic N2 disease in patients with clinical N0-1 non-small cell lung cancer.
• CEA demonstrates a role in predicting metastasis to mediastinal lymph nodes, suggesting its utility beyond traditional monitoring.

Impact:

• Accurate monitoring of small cell lung cancer using pro-GRP can lead to timely treatment adjustments.
• Identifying predictors of advanced disease (N2) allows for more precise staging and potentially tailored therapeutic strategies in non-small cell lung cancer.
• Enhanced understanding of tumor marker roles may improve relapse prediction and treatment efficacy, ultimately benefiting patient outcomes.